Does PSA at less than 20 exclude the diagnosis of metastatic prostate cancer?;Un PSA inférieur à 20 ng/ml exclue-t-il le diagnostic de cancer de prostate métastatique?

Progres en Urologie

Volumn 8, Issue 6, 1998, Pages 1018-1021

  Amsellem, Delphine ^a   Ogiez, Nicolas ^a   Salomon, Laurent ^a   Chopin, Dominique ^a   Abbou, Claude Clément ^a   Colombel, Marc ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b Service d'Urologie   (France)

Author keywords

Bone scan; Diagnosis; Metastases; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOPSY; BLOOD; BONE TUMOR; COMPARATIVE STUDY; FOLLOW UP; HUMAN; MALE; METASTASIS; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; SCINTISCANNING; TIME;

AGED; BIOPSY; BONE NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0032245803     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. CATALONA W.J., SMITH D.S., RATLIFF T.L., DODDS K.M., COPLEN D.E., TUAN J.J., PETROS J.A., ANDRIOLE G.L. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N.E.M.J., 1991, 324, 1156-1161.
2. D'AMICO A.V., WHITTINGTON R., MALKOWICZ S.B., SCHULTZ D., SCHNALL M., TOMASZEWSKI J.E., WEIN A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol., 1995, 154, 131-138.
3. GLEASON D.F., MELLINGER G. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 1974, 111, 58-64.
4. CLEAVE M.E., COUPLAND M., DRACHENBERG D., COHEN L., KWONG S., GOLDENBERG S L., SULLICAN L.D. Ability of serum prostate specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology, 1996, 47, 708-712.
5. HAUKAAS S., ROERVIK J., HALVORSEN O.J., FOELLING M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br. J. Urol., 1997, 79, 770-776.
6. HUNCHAREK M., MUSCAT J. Serum prostate specific antigen as a predictor of staging abdominal pelvic computed tomography in newly diagnosed prostate cancer. Abdom. Imaging, 1995, 21, 364-367.
7. JANKNEGT R.A., ABBOU C.C., BARTOLETTI R., BERNSTEINHAHN L., BRACKEN B., BRISSET J.M., CALAIS DA SILVA F., CHISHOLM G.D., CRAWFORD E.D., DEBRUYNE F.M.J., DJIKMAN G.D., FRICK J., GOEDHALS L., KNONAGEL H., VENNER P.M. Orchidectomy and nilutamide or placebo as treatment of metastatic prostate cancer in a multinational double blind randomized trial. J. Urol., 1993, 157, 1329-1334.
8. JOHANSSON I.E., ADAMI H.O., ANDERSON S.O., BERGSTROM R., KRUSEMO U.B., KRAAZ W. Natural history of localised prostatic cancer. Lancet, 1989, 1, 799-803.
9. JORGENSEN T., MULLER C., KAAHLU O., DANIELSEN H.E., TVETER J. Extent of disease based on initial bone scan : important prognostic predictor for patients with metastatic prostatic cancer. Eur. J. Urol., 1995, 28, 40-46.
10. KABALIN J N., Mc NEAL J E , JOHNSTONE I.M . STAMEY T.A. Serum prostate specific antigen and the biologic progression of prostate cancer. Urology. 1995, 46, 65-70.
11. LABRIE F., CANDAS B., GOMEZ J.L., DIAMOND P., SUBURU R., LEMAY M. Diagnosis of a dvanced or non curable prostate cancer can be practically eliminated by prostate specific antigen. Urology, 1995, 47, 212-217.
12. LEVRAN Z., GONZALES J.A., DIOKNO A C., JAFRI S.H.Z., STEINERT B.W. Are pelvic computed tomography, bone scan and pelvic lumphadectomy necessary in the staging of prostatic cancer Br. J. Urol., 1995, 75, 778-781.
13. MERRICK M.V., DING C L., CHISHOLM G.D., ELTON R.A. Pronostic singificance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. Br. J. Urol., 1985, 57, 715-720.
14. MILLER PD., EARDLEY I., KIRBY R.S. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br. J. Urol., 1992, 70, 295-298.
15. MURPHY P.G., NATARAJAN N., PONTES J.E., SCHMIDT R.I., SMART C.R , SCHMIDT J.D., METTLIN C. The national survey of prostate cancer in the United States by the American College of Surgeons. J. Urol., 1997, 127, 928-934
16. NARAYAN P., FOURNIER G., GAJENDRAN V., LEIDICH R., LO R., WOLF J.S., JACOB G., PALMER K., FREIHA F. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology. 1994, 44, 519-524.
17. OHORI M , WHEELER T.M., DUNN J.K., STAMEY T.A., SCARDINO P. The pathologic features and prognosis of prostate cancer detectable with current diagnostic tests J. Urol., 1994, 152, 1714-1717.
18. PARKER S.L., TONG T., BOLDEN S., WINGO P.A. Cancer statistics, 1997, C.A. Cancer J. Clin., 1997, 47, 5-27.
19. RAVERY V., BOCCON-GIBOD L.A., DAUGE-GEFFROY M.C., BILLEBAUD T., DELMAS V., MEULEMANS A., TOUBLANC M., BOCCON-GIBOD L. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology, 1994, 44, 371-376.
20. RAVERY V., SCHMID H.P., TOUBLANC M., BOCCON-GIBOD L. Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma? Cancer, 1996, 78, 1079-1084.
21. SALOMON L., COLOMBEL M., PATARD J.I., BELLOT J., CHOPIN D., ABBOU C.C. Three mid additional biopsies improve local assessment in patients with one positive biopsy. Eur. J. Urol., 1997, in press
22. SISSONS G.R.J., CLEMENTS R., PEELING W.B., PENEY M.D. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer. Br. J. Radiol., 1992, 65, 861-864.
23. VETERANS ADMINISTRATION COOPERATIVE UROLOGICAL RESEARCH GROUP. Treatment and survival of patients with cancer of the prostate. Surg. Gynecol. Obstet., 1967, 124, 1011-1017.